Loading...
XKRX
003000
Market cap263mUSD
Dec 05, Last price  
3,940.00KRW
1D
-0.13%
1Q
12.57%
Jan 2017
-78.66%
Name

Bukwang Pharm Co Ltd

Chart & Performance

D1W1MN
XKRX:003000 chart
P/E
P/S
2.43
EPS
Div Yield, %
Shrs. gr., 5y
-0.93%
Rev. gr., 5y
-0.98%
Revenues
160.09b
+27.13%
137,523,643,000155,670,536,000161,578,385,000170,810,033,000180,621,167,000101,218,841,170147,525,248,350130,794,936,620141,687,310,090142,132,090,470138,617,593,780150,743,453,790194,223,518,400168,193,616,060169,659,753,510182,491,221,470190,909,364,530125,928,240,770160,086,870,000
Net income
-2.64b
L-91.57%
19,546,836,00032,820,365,00030,880,035,00027,873,116,00027,394,121,0006,406,124,93016,511,914,53019,532,034,47023,616,206,94025,139,405,30015,807,434,67011,090,626,650145,670,056,220-7,434,843,160-10,104,662,060-2,796,797,660-4,248,677,010-31,329,660,640-2,641,326,000
CFO
34.36b
P
23,265,988,00027,874,618,000-2,748,946,00015,417,164,00033,565,101,00033,120,756,53049,499,634,11036,515,220,60027,862,826,03010,297,553,570-7,763,106,3508,562,581,7206,816,640,980-23,407,507,620723,168,74026,524,994,28016,461,450,020-10,500,408,02734,361,977,000
Dividend
Dec 29, 2021100 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Bukwang Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It manufactures oral solid dosage forms, injections, oral solutions, external-use solutions, and ointments. The company offers products in various therapeutic areas, including liver disease treatments, such as Levovir and Legalon; diabetic complication products comprising Dexid and Thioctacid; CNS disorder drugs consisting of Lonasen, Ixel, and Orfil; and respiratory disease treatments, which comprise Azeptin and Asima. It also provides OTC products; toothpastes, and hair and skin care goods; and nutritional supplements. In addition, the company offers products for antihistamines, hepatitis and gastrointestinal, sedative and antidote, anti-cancer, thyroid and osteoporosis, diabetes, obstetrics, urinogenital, cardiovascular, dermatology, obesity, pain relief, and muscle relaxant. Further, it provides products for bruises, skin and mucous membrane, rhinitis, cold symptoms, cough, phlegm and asthma, rheumatoid arthritis, osteoarthritis, pain caused by cold and fever, dysmenorrhea, NSAIDs, inflammation, joint inflammation, tinea pedis, infected wounds, dermatitis, antivirals-herpes, eczema, diarrhea, dyspepsia, sense of distension, anti-histamine, anti-ulcer, constipation, anemia, pregnant multivitamins, candidiasis, athlete's foot, onychomycosis, stomatitis, pimple, acne, physical fatigue, neuralgia, myalgia, and arthralgia. Additionally, the company offers medicines for period of lactation, rickets, night blindness, varicose vein, and sputum; and quasi drugs and medical devices, as well as health functional food. It also develops anti-diabetes compound with Melior Pharmaceuticals; and anti-cancer drugs with LSK BioPartners, as well as cell therapies using adult stem cells, as well as holds a license for a novel candidate to treat movement disorder in Parkinson's disease patients. The company was founded in 1960 and is based in Seoul, South Korea.
IPO date
Aug 05, 1988
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT